1. Home
  2. NTRA vs LII Comparison

NTRA vs LII Comparison

Compare NTRA & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • LII
  • Stock Information
  • Founded
  • NTRA 2003
  • LII 1895
  • Country
  • NTRA United States
  • LII United States
  • Employees
  • NTRA N/A
  • LII N/A
  • Industry
  • NTRA Medical Specialities
  • LII Industrial Machinery/Components
  • Sector
  • NTRA Health Care
  • LII Industrials
  • Exchange
  • NTRA Nasdaq
  • LII Nasdaq
  • Market Cap
  • NTRA 21.5B
  • LII 20.6B
  • IPO Year
  • NTRA 2015
  • LII 1999
  • Fundamental
  • Price
  • NTRA $171.86
  • LII $550.20
  • Analyst Decision
  • NTRA Strong Buy
  • LII Hold
  • Analyst Count
  • NTRA 16
  • LII 12
  • Target Price
  • NTRA $185.56
  • LII $590.64
  • AVG Volume (30 Days)
  • NTRA 1.2M
  • LII 383.5K
  • Earning Date
  • NTRA 08-07-2025
  • LII 07-23-2025
  • Dividend Yield
  • NTRA N/A
  • LII 0.95%
  • EPS Growth
  • NTRA N/A
  • LII 30.10
  • EPS
  • NTRA N/A
  • LII 22.45
  • Revenue
  • NTRA $1,831,000,000.00
  • LII $5,366,800,000.00
  • Revenue This Year
  • NTRA $19.92
  • LII $3.33
  • Revenue Next Year
  • NTRA $16.02
  • LII $5.56
  • P/E Ratio
  • NTRA N/A
  • LII $24.41
  • Revenue Growth
  • NTRA 51.50
  • LII 7.78
  • 52 Week Low
  • NTRA $92.14
  • LII $500.10
  • 52 Week High
  • NTRA $183.00
  • LII $682.50
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 66.42
  • LII 45.97
  • Support Level
  • NTRA $161.39
  • LII $536.69
  • Resistance Level
  • NTRA $169.17
  • LII $564.00
  • Average True Range (ATR)
  • NTRA 4.86
  • LII 11.09
  • MACD
  • NTRA 0.57
  • LII -1.25
  • Stochastic Oscillator
  • NTRA 90.95
  • LII 48.08

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About LII Lennox International Inc.

Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.

Share on Social Networks: